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The Success of Sinister Right-Handers in Baseball
To the Editor: Left-handed people possess less 
hemispheric lateralization than right-handers,1 
meaning that there is generally less differentia-
tion between the functions of the right and left 
hemispheres of the brain. In a letter published in 
the Journal in 1982, McLean and Ciurczak2 claimed 
that in baseball this lack of lateralization pro-
vides a relative advantage to batters who both 
throw and bat left-handed. They found an over-
representation of left-handed batters in profes-
sional baseball, relative to lesser-skilled controls, 
and higher batting averages among professionals 
who throw left-handed and bat left-handed than 
among those who throw right-handed and bat 
left-handed or those who throw right-handed and 
bat right-handed (Table 1). However, our re-
analysis, 35 years later, shows an oversight that 
could have supported a very different conclusion.
The odds ratios that we calculated on the basis 
of the original 1982 data confirm that profes-
sional baseball batters who throw left-handed 
and bat left-handed are overrepresented relative 
to controls (odds ratio, 2.45; 95% confidence 
interval [CI], 1.63 to 3.69). However, the earlier 
analysis missed the much greater advantage for 
players who throw right-handed and bat left-
handed (odds ratio, 7.60; 95% CI, 4.20 to 13.77). 
The benefit was even more striking when the 
odds ratios for becoming one of the top hitters, 
designated as those with a career batting aver-
age of 0.299 or higher, were compared (odds 
ratio, 3.88 [95% CI, 2.30 to 6.55] among players 
who throw left-handed and bat left-handed vs. 
18.71 [95% CI, 9.73 to 36.01] among those who 
throw right-handed and bat left-handed), a finding 
supported by our newly collected data (Table 1).
The advantage of throwing right-handed and 
batting left-handed in becoming a professional 
also extends to an advantage when a player is 
competing in the major leagues. With data ag-
gregated across all major-league players (from 
1871 through 2016), those who throw right-
handed and bat left-handed are more likely to 
have a career batting average of 0.299 or higher 
than are those who throw left-handed and bat 
left-handed (odds ratio, 3.46 [95% CI, 2.60 to 4.59] 
vs. 1.42 [95% CI, 1.03 to 1.95]). In contrast to 
the earlier analysis by McLean and Ciurczak, our 
analyses of the career batting averages of players 
with an average of 0.299 or higher and of players 
in the National Baseball Hall of Fame (Table 1) 
showed no significant differences between those 
who throw left-handed and bat left-handed and 
those who throw right-handed and bat left-
handed (P = 0.16 for batting average ≥0.299 and 
P = 0.12 for Hall of Fame).
Batters who adopt a left-handed stance enjoy 
a range of potential benefits3: the limited experi-
ence opponents have pitching to left-handers, an 
increased likelihood of “off-handed” match-ups 
against right-handed pitchers, the direction of 
the bat-swing moving momentum toward first 
base (to which the batter already stands closer), 
potential asymmetries in the location of fielders 
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and their skill level, and a possible tendency to 
be selected on a team to allow a more flexible 
strategy.4 We speculate that players who throw 
right-handed and bat left-handed enjoy an addi-
tional biomechanical advantage, with the domi-
nant (throwing) hand being placed further from 
the hitting end of the bat, providing a longer 
lever with which to hit the ball (potentially at 
the expense of bat control5). Given these sport-
specific explanations, our findings argue against 
any advantage due to hemispheric lateralization.
David L. Mann, Ph.D.
Vrije Universiteit Amsterdam 
Amsterdam, the Netherlands
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Dabigatran Reversal with Idarucizumab
To the Editor: Data provided by Pollack and 
colleagues (Aug. 3 issue)1 suggest a dissociation 
between the normalization of the coagulation 
profile and the establishment of effective hemo-
stasis after the administration of idarucizumab 
in patients with uncontrolled bleeding. The median 
time to the cessation of bleeding was 2.5 hours 
among patients with nonintracranial hemorrhage. 
In analyses reported separately, the median time to 
the cessation of bleeding was 3.5 hours among pa-
tients with gastrointestinal bleeding and 4.5 hours 
among those with nonintracranial and nongastro-
intestinal bleeding.2 The median time to the ces-
sation of bleeding was 11.4 hours when intracra-
nial hemorrhage was included in the analysis 
involving patients with serious bleeding.3 Should 
clinicians rely solely on idarucizumab and hope 
that their patients do not die from uncontrolled 
hemorrhage while waiting for hemostasis to be 
established? A reasonable approach would be to 
administer blood-component therapy (e.g., pro-
thrombin complex concentrate and activated pro-
thrombin complex concentrate) — a bridge be-
tween the normalization of the coagulation profile 
and the establishment of hemostasis, according 
to in vitro and preclinical data4,5 — in addition to 
idarucizumab. It can be reasonably argued that 
the establishment of effective hemostasis with 
blood-component and idarucizumab therapy out-
weighs the risk of thrombotic adverse events 
among patients with serious hemorrhaging. The 
effectiveness and need for further blood-compo-
nent and idarucizumab therapy may be assessed 
by serial clinical assessments and a serial profile 
of clotting times.
Luke Yip, M.D.
Rocky Mountain Poison and Drug Center 
Denver, CO 
luke . yip@ rmpdc . org
Jou-Fang Deng, M.D.
Taipei Veterans General Hospital 
Taipei, Taiwan
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To the Editor: In 2015, an interim analysis in-
volving 51 patients with acute bleeding who had 
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